MiniMed 780G Associated With Reduced HbA1c, Increased Time in Range

Real-world data evaluating the MiniMed™ 780G advanced hybrid closed-loop (AHCL) insulin pump system showed HbA1c decreased from 8.46% at baseline to 7.76% following initiation of the device (P = .0018) in a cohort of 52 patients with diabetes.

Findings from the single-center retrospective analysis were presented at the Endocrine Society Annual Meeting 2026 in Chicago, Illinois, from June 13-16. Investigators reported a mean time in range (TIR) of 71.1%, exceeding the recommended target of ≥70%, alongside a mean time below 54 mg/dL of 0.08%, well below the <1% threshold for clinically significant hypoglycemia.

“The MiniMed 780G was associated with meaningful improvements in glycemic control while maintaining a low risk of severe hypoglycemia in routine clinical practice,” study investigator Sehrish Noorali, MD, a physician resident at St. Francis Emory Healthcare, and colleagues wrote.

The MiniMed 780G combines continuous glucose monitoring with automated insulin delivery technology designed to optimize glycemic control while reducing hypoglycemia risk.

The retrospective study evaluated 52 patients with diabetes who initiated the MiniMed 780G system. Participants had a mean baseline HbA1c of 8.46% (standard deviation [SD], 1.91%). Study investigators assessed glycemic outcomes using device-derived glucose management indicator (GMI), TIR, and time spent < 54 mg/dL, in addition to HbA1c values obtained from the electronic medical record.

Study investigators also stratified patients by use of manufacturer-recommended settings in a subgroup analysis. Of the study population, 28 patients were classified as using recommended settings (Rec+), and 17 were classified as using non-recommended settings (Rec−). In total, 7 patients with undocumented settings were excluded from subgroup analyses.

Subgroup analyses suggested adherence to recommended settings may enhance glycemic benefits. Patients in the Rec+ group experienced a greater reduction in HbA1c than those in the Rec− group (1.14% vs 0.49%). The reduction reached statistical significance in the Rec+ group (P = .006) but not in the Rec− group (P = .055).

Investigators also observed significantly increased TIR among Rec+ patients compared with Rec− patients (75.5% vs 67.6%; P = .037). While mean GMI trended lower in the Rec+ group (6.99% vs 7.21%; P = .07), the difference did not reach statistical significance.

Based on these findings, investigators suggested that counseling patients on manufacturer-recommended settings at initiation may represent a practical strategy for maximizing the benefits of AHCL therapy.

Future analyses will examine whether use of the MiniMed 780G system is associated with reductions in hypoglycemia- or hyperglycemia-related emergency department visits and hospitalizations compared with multiple daily injection therapy or conventional insulin pump therapy without closed-loop automation.

References

1. Noorali S, Tandon R, Muldrow B, Serrano JT, Roboubiat A, Baliga BS. Glycemic outcomes with the MiniMed™ 780G advanced hybrid closed-loop system: real-world improvements in HbA1c, time in range, and hypoglycemia safety. Poster presented at: ENDO 2026: The Endocrine Society Annual Meeting; June 13, 2026; Chicago, IL. Poster SAT-875.

2. Bhargava A, Bergenstal RM, Warren ML, et al. Safety and Effectiveness of MiniMedTM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes. Diabetes technology & therapeutics. 2025;27(5):366-375. doi:https://doi.org/10.1089/dia.2024.0586